Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

INOVIO PHARMACEUTICALS, INC.

(INO)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
10/18/2021 10/19/2021 10/20/2021 10/21/2021 10/22/2021 Date
7.02(c) 7.13(c) 7.04(c) 7.04(c) 6.74 Last
1 905 132 2 415 402 2 006 682 2 047 950 4 050 919 Volume
0.00% +1.57% -1.26% 0.00% -4.26% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 4,71 M - -
Net income 2021 -272 M - -
Net Debt 2021 - - -
P/E ratio 2021 -5,41x
Yield 2021 -
Sales 2022 98,7 M - -
Net income 2022 -157 M - -
Net Debt 2022 - - -
P/E ratio 2022 -9,64x
Yield 2022 -
Capitalization 1 481 M 1 481 M -
Capi. / Sales 2021 315x
Capi. / Sales 2022 15,0x
Nbr of Employees 262
Free-Float 98,3%
More Financials
Company
Inovio Pharmaceuticals, Inc. (Inovio) is a late-stage biotechnology company, which is involved in developing deoxyribonucleic acid (DNA) immunotherapies and vaccines focused on treating and preventing cancers and infectious diseases. The Company's DNA-based immunotherapies, in combination with its electroporation delivery devices, generates immune responses, in particular T cells, in the body to fight target... 
More about the company
Ratings of Inovio Pharmaceuticals, Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
C+
More Ratings
All news about INOVIO PHARMACEUTICALS, INC.
10/21INOVIO PHARMACEUTICALS : to Collaborate With Colombian Government in Combating COVID-19
MT
10/12INOVIO PHARMACEUTICALS : Announces Online Preprint Publication of Homologous Boosting Data..
PR
10/12Inovio Pharmaceuticals, Inc. Announces Online Preprint Publication of Homologous Boosti..
CI
10/11INOVIO PHARMACEUTICALS : Secures Approval to Conduct Phase 3 Trial of COVID-19 DNA Vaccine..
MT
10/11INOVIO PHARMACEUTICALS : Expands INNOVATE Phase 3 for INO-4800, its DNA Vaccine Candidate ..
PR
10/11INOVIO Expands Phase 3 for INO-4800, its DNA Vaccine Candidate for COVID-19, to include..
CI
09/29INOVIO PHARMACEUTICALS : to Present Three Posters at IDWeek 2021
PR
09/22INOVIO PHARMACEUTICALS : Gets Approval from Mexico Regulator for COVID-19 Vaccine Efficacy..
MT
09/22INOVIO PHARMACEUTICALS : Receives Regulatory Authorization to Conduct Phase 3 Efficacy Tri..
PR
09/22INOVIO Receives Regulatory Authorization to Conduct Phase 3 Efficacy Trial of its COVID..
CI
09/10INOVIO PHARMACEUTICALS : BofA Securities Downgrades Inovio Pharmaceuticals to Underperform..
MT
09/01INOVIO PHARMACEUTICALS : to Present at Upcoming Investor Conferences in September
PR
08/26INOVIO PHARMACEUTICALS : Receives Authorization From Brazil Regulator to Start Phase 3 Tri..
MT
08/26INOVIO PHARMACEUTICALS : Receives Authorization to Conduct Phase 3 Efficacy Trial of its C..
PR
08/26INOVIO Receives Authorization to Conduct Phase 3 Efficacy Trial of its Covid-19 DNA Vac..
CI
More news
News in other languages on INOVIO PHARMACEUTICALS, INC.
10/21Inovio Pharmaceuticals va collaborer avec le gouvernement colombien dans la lutte contr..
10/11Inovio Pharmaceuticals obtient l'autorisation de mener un essai de phase 3 sur le candi..
09/22Inovio Pharmaceuticals obtient l'approbation de l'organisme de réglementation mexicain ..
08/11CORONA-BLOG/China genehmigt Testreihe mit zwei Corona-Vakzinen
04/23MISE À JOUR SECTORIELLE : Les actions du secteur de la santé ont enregistré des gains modé..
More news
Analyst Recommendations on INOVIO PHARMACEUTICALS, INC.
More recommendations
Chart INOVIO PHARMACEUTICALS, INC.
Duration : Period :
Inovio Pharmaceuticals, Inc. Technical Analysis Chart | INO | US45773H2013 | MarketScreener
Technical analysis trends INOVIO PHARMACEUTICALS, INC.
Short TermMid-TermLong Term
TrendsBearishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 10
Last Close Price 7,04 $
Average target price 13,22 $
Spread / Average Target 87,8%
EPS Revisions
Managers and Directors
J. Joseph Kim President, Chief Executive Officer & Director
Peter D. Kies Chief Financial Officer
Simon X. Benito Chairman
Laurent M. Humeau Chief Scientific Officer
Kate E. Broderick Senior Vice President-Research & Development
Sector and Competitors
1st jan.Capi. (M$)
INOVIO PHARMACEUTICALS, INC.-20.45%1 481
MODERNA, INC.225.04%137 066
LONZA GROUP AG32.03%60 786
IQVIA HOLDINGS INC.42.23%48 830
SEAGEN INC.-0.71%31 638
CELLTRION, INC.-38.86%25 233